原发性上皮性卵巢癌减瘤术中腹腔热灌注化疗的肿瘤学结局与并发症:系统综述与荟萃分析
该系统综述与荟萃分析纳入35项研究共2252例原发性上皮性卵巢癌患者,评估减瘤术中行腹腔热灌注化疗(HIPEC)的肿瘤学结局与围手术期并发症。仅1项随机试验和6项研究设手术对照组,HIPEC方案异质性大,3年总生存率46-77%,30天III-IV级并发症合并比例34%(95%CI 20-52),术后死亡0%(95%CI 0-5)。
要点
- 仅1项随机试验支持间歇性减瘤术中行HIPEC可改善总生存。
- HIPEC方案(时机、温度、药物)在研究间差异显著,缺乏统一标准。
- 30天III-IV级并发症合并比例为34%,术后死亡为0%。
核心结论
- 一项随机试验提示原发性上皮性卵巢癌间歇性减瘤术中可考虑HIPEC。
- 文献在HIPEC方案及短期和长期结局方面存在显著异质性。
- 亟需高质量前瞻性随机试验明确HIPEC在一线治疗中的作用。
研究设计与样本
- 系统综述与荟萃分析,检索MEDLINE、EMBASE、Cochrane CENTRAL和Cochrane系统综述数据库至2019年8月。
- 纳入35篇文章共2252例原发性上皮性卵巢癌患者,其中1项随机试验,仅6项研究设手术对照组。
- 使用Institute of Health Economics质量评估清单、Newcastle-Ottawa量表和Cochrane协作工具评估偏倚风险。
主要发现
- 报告的总生存率高度可变,3年总生存率范围为46-77%。
- 3项比较性队列研究和唯一随机试验报告HIPEC较单纯手术有统计学显著生存获益,2项比较性队列研究未报告。
- 30天III-IV级并发症合并比例为34%(95%CI 20-52),术后死亡合并比例为0%(95%CI 0-5)。
关键数值与推荐
- 3年总生存率范围46-77%。
- 30天III-IV级并发症合并比例34%(95%CI 20-52)。
- 30天术后死亡合并比例0%(95%CI 0-5)。
临床怎么用
- 基于一项随机试验,原发性上皮性卵巢癌间歇性减瘤术中可考虑HIPEC。
- 因方案异质性大,临床应用需谨慎选择患者和HIPEC方案。
- 需等待高质量前瞻性随机试验进一步明确HIPEC的一线治疗地位。
局限性
- 仅1项随机试验,多数为观察性研究且仅6项设手术对照组。
- HIPEC的时机、温度和化疗药物在各研究间差异显著。
- 文献异质性大,短期和长期结局报告不一致。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Heated intraperitoneal chemotherapy (HIPEC) has not been universally adopted at the time of interval cytoreductive surgery for primary epithelial ovarian cancer (EOC) despite evidence of a 12-month overall survival (OS) benefit in a recent landmark randomized trial. We performed a systematic review and meta-analysis to assess oncologic outcomes and perioperative morbidity following HIPEC among primary EOC patients. METHODS: We searched MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials, and the Cochrane Database of Systematic Reviews, from inception to August 2019, for observational and randomized studies of primary EOC patients undergoing HIPEC. We assessed risk of bias using the Institute of Health Economics Quality Appraisal Checklist for single-arm cohort studies, Newcastle-Ottawa Scale for comparative cohort studies, and Cochrane Collaboration's Tool for randomized trials. We qualitatively summarized survival outcomes and calculated the pooled proportion of 30-day grade III-IV morbidity and postoperative death. RESULTS: We identified 35 articles including 2252 primary EOC patients; one study was a randomized trial, and only six studies included a comparator group of surgery alone. The timing, temperature, and chemotherapeutic agents used for HIPEC differed across studies. Reported OS was highly variable (3-year OS range: 46-77%); three comparative cohort studies and the sole randomized trial reported statistically significant survival benefits for HIPEC over surgery alone, while two comparative cohort studies did not. The pooled proportions for grade III-IV morbidity and postoperative death at 30 days were 34% (95% CI 20-52) and 0% (95% CI 0-5) respectively. CONCLUSION: One randomized trial suggests that HIPEC at time of interval cytoreductive surgery should be considered in patients with primary EOC. However, there is significant heterogeneity in literature with respect to an appropriate HIPEC regimen, short- and long-term outcomes. High-quality prospective randomized trials are urgently needed to clarify the role of HIPEC in the first-line treatment of primary EOC.
引用
- Bouchard-Fortier G, Cusimano MC, Fazelzad R, et al. Oncologic outcomes and morbidity following heated intraperitoneal chemotherapy at cytoreductive surgery for primary epithelial ovarian cancer: A systematic review and meta-analysis. Gynecol Oncol. 2020. PMID: 32387131. doi:10.1016/j.ygyno.2020.03.034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。